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A B S T R A C T
The development and full validation of a sensitive and selective ultra-performance liquid chromatography/
tandem mass spectrometry (UPLC–MS/MS) method are described for the simultaneous analysis of afatinib,
alectinib, crizotinib and osimertinib in human lithium heparinized plasma. Afatinib-d6, crizotinib-d5 and er-
lotinib-d6 were used as internal standards. Given osimertinib's instability in plasma and whole blood at ambient
temperature, samples should be solely processed on ice (T=0 °C). Chromatographic separation was obtained on
an Acquity UPLC ® BEH C18; 2.1× 50mm, 1.7 μm column, which was eluted with 0.400mL/minute flow on a
linear gradient, consisting of 10mM ammonium formate (pH 4.5) and acetonitrile. Calibration curves for all
compounds were linear for concentration ranges of 1.00 to 100 ng/mL for afatinib and 10.0 to 1000 ng/mL for
alectinib, crizotinib and osimertinib, herewith validating the lower limits of quantification at 1.00 ng/mL for
afatinib and 10.0 ng/mL for alectinib, crizotinib and osimertinib. Within-run and between-run precision mea-
surements fell within 10.2%, with accuracy ranging from 89.2 to 110%.
1. Introduction
Molecular pathology has become a diagnostic keystone of the
treatment for non-small cell lung cancer (NSCLC). As a result of precise
determination of driver mutations and better insight in tumor behavior,
a more tailored therapy can be given to patients. In the last decade, this
resulted in the development and registration of targeted therapies with
multi-kinase inhibitors (MKIs). With the introduction of MKIs, pro-
mising outcome data have been achieved; both survival and quality of
life improved significantly [1,2].
Epidermal growth factor receptor (EGFR) is with approximately
17% the most frequently determined NSCLC mutation, followed by
anaplastic lymphoma kinase (ALK) with circa 7% [3]. Afatinib is an
orally bioavailable MKI registered as first line treatment for locally
advanced and metastatic NSCLC with EGFR mutations [4]. Disease
progression under first line EGFR MKI therapy is in 49 to 66% caused by
the EGFR exon 20 T790M point mutation [5–8]. For this escape me-
chanism, osimertinib was developed as second line MKI [9]. However,
recently, promising data prompted registration of osimertinib to be-
come first line treatment for EGFR mutated NSCLC [10]. Crizotinib is
registered as first line treatment of ALK and ROS1 mutated locally ad-
vanced and metastatic NSCLC [11]. Alectinib is also an ALK inhibitor
and is approved as first line treatment for ALK mutated NSCLC or as
second line MKI after crizotinib [12].
Ultra-performance liquid chromatography tandem mass spectro-
metric (UPLC-MS/MS) assays to quantify these lung cancer MKIs (afa-
tinib, alectinib, crizotinib and osimertinib) have already been devel-
oped separately using different methods [13–16]. However, a multi-
assay for these agents has not been developed before. Strikingly, Rood
et al. and Dickenson et al. reported contrasting data on osimertinib's
stability in plasma [15,17]. Dickenson et al. reported data suggesting
osimertinib to be highly unstable, whereas Rood et al. suggested that
osimertinib remains stable for a few hours at room temperature. This
discrepancy needs further clarification, since the outcome will have
vast implications for handling of patient samples.
Pharmacokinetics of MKIs are increasingly being studied to in-
vestigate for example exposure-response or exposure-toxicity relation-
ships, the impact of drug-drug interactions [18], or the contribution of
MKI pharmacokinetics in the development of drug resistance. Sub-
sequent implementation of Therapeutic Drug Monitoring could
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optimize individual treatment further by increasing efficacy and lower
toxicity [19]. Therefore, it is very important to quantify the selected
MKIs in plasma. Aim of this study was hence to develop a quantitative
UPLC-MS/MS method for the simultaneous determination of afatinib,
alectinib, crizotinib and osimertinib in human plasma.
2. Experimental
2.1. Chemicals
Afatinib (C24H25ClFN5O3), alectinib (C30H34N4O2) as hydrochloride
(HCl) salt and osimertinib (C28H33N7O2) were purchased from LC
Laboratories (Woburn, USA). Crizotinib (C21H22Cl2FN5O) was pur-
chased from Sigma-Aldrich (Saint Louis, USA). All MKIs had purities
of> 99%. Labeled internal standards afatinib-d6, crizotinib-d5 and
erlotinib-d6 were acquired from Toronto Research Chemicals (Toronto,
Canada). Different batches of human drug-free lithium heparinized
plasma originated from Biological Specialty Corp. (Colmar, USA).
Nitrogen (Nitrogen 3.0, purity 99.9%) was supplied by LindeGas
(Schiedam, The Netherlands). Acetonitrile, pure water and methanol
originated from Biosolve BV (Valkenswaard, The Netherlands).
Dimethylsulfoxide (DMSO) was purchased from Sigma-Aldrich. Formic
acid was provided by JT Baker BV (Deventer, The Netherlands). All
chemicals were of analytical grade or higher.
2.2. Calibration
Three separate stock solutions, all within 5% of each other, of afa-
tinib, alectinib, crizotinib and osimertinib were formulated with DMSO
at concentrations of 1.00mg/mL. The stock solutions were preserved at
T < −70 °C. Independent stock solutions were used for the formation
of calibration standards and preparation of quality control (QC) sam-
ples. An additional solution containing 10.0 μg/mL afatinib and 100 μg/
mL alectinib, crizotinib and osimertinib was prepared to serve in the
titration of calibration curve standards.
Internal standards afatinib-d6, crizotinib-d5 and erlotinib-d6 were
dissolved in DMSO to obtain concentrations of 1mg/mL and preserved
at T < −20 °C. Internal standard solutions were subsequently 10,000-
fold diluted with acetonitrile, obtaining a 100 ng/mL internal standard
working solution which was stored at T < 8 °C and no longer used than
three months.
For each run fresh calibration standards were prepared in duplo by
addition of 10-μL aliquots of appropriate dilutions to 190-μL aliquots of
human lithium heparinized plasma to obtain concentrations of 1.00,
2.00, 5.00, 10.0, 20.0, 50.0, 90.0 and 100 ng/mL for quantitation of
afatinib and 10.0, 20.0, 50.0, 100, 200, 500, 900 and 1000 ng/mL for
quantitation of alectinib, crizotinib and osimertinib.
Pools of QC samples for the calibration standard curve of
1.00–100 ng/mL were formulated in human plasma to obtain con-
centrations of 1.00, 3.00, 40.0, 80.0 and 800 ng/mL for the lower limit
of quantification (LLQ) and QC's low, middle, high and diluted re-
spectively. The QC sample concentrations for the 10.0–1000 ng/mL
calibration standard curve were 10.0, 30.0, 400, 800 and 8000 ng/mL
for LLQ and QC's low, middle, high and diluted respectively. Prior to
processing, QC diluted was processed after a 20-fold dilution in blank
plasma. Pools of QC samples were aliquoted and stored at T < −70 °C.
2.3. Sample pretreatment
Aliquots of 100 μL internal standard solution were added to 25 μL of
plasma sample in polypropylene vials of 1.5mL. Hereafter, all samples
underwent vigorous vortex mixing for 5 s and were centrifuged
(18,000×g) for 10min at room temperature. Subsequently, super-
natants were pipetted into a 350 μL 96-well plate, that was placed
within a self-cooled (T=10 °C) autosampler, which injected quantities
of 5 μL into the UPLC-MS/MS column.
2.4. Chromatography
The UPLC-MS/MS system originated from Waters Chromatography
BV (Etten-Leur, The Netherlands) and included a Waters Acquity UPLC
I-Class Binary Solvent Manager connected with a Waters XEVO TQ-S
Micro Detector.
2.4.1. Data processing
MassLynx V4.1 SCN945 Software was utilized to collect, process and
display data. QuanLynx (as part of MassLynx Software) was used for
sample calculations and quantification.
2.4.2. Chromatographic settings
An Acquity UPLC® BEH C18 column 1.7 μm, 50mm×2.1mm,
(Waters Chromatography BV) was heated at T= 40 °C to separate
analytes. A gradient with a flow rate of 0.400mL per minute was
constructed with mobile phase A (10mM ammonium formate, having
pH 4.5) and mobile phase B (pure acetonitrile acidified by formic acid
0.1%) followed by a 5 μL partial loop injection. For incipient con-
ditioning, separation by a linear gradient was achieved, using 20% to
40% of mobile phase B from 0 to 1.0 min, then 40% to 90% of mobile
phase B during 1.0 min and keeping this for 1.0 min before resetting to
20% mobile phase B from minute 3.0 to 5.0. The overall running time
for each sample was 5min. The needle washing solvent consisted of
water/acetonitrile/2-propanol/methanol/formic acid (25:25:25:25:0.1,
v/v/v/v/v). Column effluent went past the mass spectrometer for
monitoring.
2.4.3. Tandem mass spectrometry
The cation electrospray ionization modus was used to execute
tandem mass spectrometry (MS/MS). Mass transitions in m/z were
optimized for afatinib, alectinib, crizotinib, osimertinib and the internal
standards, by infusing the specific compounds in water/acetonitrile/
formic acid (60:40:0.1, v/v/v) through mixed infusion. MS/MS para-
meters were optimized manually. The ionspray voltage was 3.00 kV.
Source and evaporation temperatures were T=150 °C and T=650 °C
respectively. Nitrogen gas was used for dissolution at 800mL per hour.
The multiple reaction monitoring (MRM) modus was used for quanti-
fication. Table 1 presents the optimal MS/MS settings for parent and
daughter ions. Collision cell Pirani pressure retained ~5e-3mbar
(argon).
2.4.4. Quantification
Calibration curves were constructed by calculating the peak area
ratio for every compound, respectively afatinib (486 > 112) to the
internal standard afatinib-d6 (492 > 371), alectinib (483 > 396) to
the internal standard erlotinib-d6 (400 > 278), crizotinib
Table 1
MS parameters of the analytes.
Analyte Parent ion Fragment ion Cone
voltage
Collision
energy
Dwell time
(m/z) (m/z) (V) (eV) (ms)
Afatinib 486.4 112.2 20 28 25
486.4 371.4 20 27 25
Alectinib 483.3 396.4 26 22 100
483.3 381.4 22 35 100
Crizotinib 450.3 260.4 25 23 10
450.3 84.2 25 30 10
Osimertinib 500.5 72.2 45 25 100
Afatinib-d6 492.0 371.2 28 27 100
492.0 118.2 28 26 25
Erlotinib-d6 400.2 339.2 20 24 100
400.2 278.2 20 35 100
Crizotinib-d5 455.0 265.2 25 22 10
455.0 89.1 25 35 10
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(450 > 260) to the internal standard crizotinib-d5 (455 > 265) and
osimertinib (500 > 72) to the internal standard erlotinib-d6
(400 > 278) against the pre-set concentration on a 1/concentration2
graphic scale.
2.5. Validation
Full validation of this UPLC–MS/MS method was performed conform
the ‘Guidance for Industry, Bioanalytical Method Validation’, defined
by the Food and Drug Administration (www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM070107.pdf).
2.5.1. Specificity and selectivity
To specifically determine the LLQ, ten different lots of blank human
plasma samples were spiked to obtain concentrations of 1.00 ng/mL for
afatinib and 10.0 ng/mL for alectinib, crizotinib and osimertinib. All
samples were analyzed simultaneously.
2.5.2. Accuracy and precision
The accuracy (ACC), within-run precision (WRP) and between-run
precision (BRP) were calculated with quantification of five com-
plementary LLQ and QC sample pools of all compounds. These were
processed separately in three consecutive runs, while analyzing cali-
bration curve standards in duplo. Calculation of ACC, WRP and BRP for
LLQ and QC samples was executed through a unidirectional analysis of
variance (i.e. one-way ANOVA), using the running cycle as variable
factor as reported by Rosing et al. [20].
2.5.3. Recovery and matrix effect
Extraction recovery (RE) was assessed through correlating MS/MS
responses of afatinib, alectinib, crizotinib and osimertinib at con-
centration levels of QC low, QC medium and QC high spiked in triplo
into blank human lithium heparinized plasma before extraction, with
MS/MS responses of the same compounds spiked in blank processed
human plasma. Matrix effect calculations were conducted by relating
the MS/MS responses of afatinib, alectinib, crizotinib and osimertinib at
concentration levels of QC low, QC medium and QC high spiked in
triplicate in six lots of blank lithium heparinized plasma, to the MS/MS
responses of the same compounds spiked in acetonitrile/water/formic
acid (40:60:0.1, v/v/v) as delineated by De Bruijn et al. [21].
2.5.4. Short-term, long-term and (autosampler) storage stability
The stability of afatinib, alectinib, crizotinib and osimertinib in
human plasma was researched using sets of plasma at concentrations of
QC low, high and diluted which were stored on ice, at ambient tem-
perature and in a water bath (T=37 °C) for 1, 2, 3, 5 and 24 h. Also
three freeze–thaw cycles were tested, wherein the samples completely
melted before refreezing for a minimum of 18 h. Subsequent long-term
stability tests at T < −70 °C were executed, making use of the earlier
specified QC samples. Autosampler stability, i.e. the stability of pro-
cessed samples which are kept in the autosampler for a pre-defined
time, was tested in triplicate with QC low, QC high and QC diluted. The
QC-samples were repeatedly injected on different time points.
2.6. Clinical applicability
To prove additional applicability of this developed bioanalytical
method in clinical practice, multiple blood samples were obtained from
five patients who were included in a clinical study that studied afatinib
which was orally taken for six weeks after a run-in phase (www.
trialregister.nl; Netherlands Trial Register study 6652). During three
24 hour hospital admissions, a total of 36 blood samples were collected
in 4mL lithium heparin blood collection tubes. After centrifuging all
samples with 2500×g at 4 °C for 10min within 10min of the blood
withdrawal, the separated plasma was isolated and preserved at
T < −70 °C until further processing. The study protocol had approval
from the institutional review board and was in consonance with the
declaration of Helsinki, cq patients provided informed consent prior to
enrollment. Moreover, blood samples from three patients treated with
alectinib, crizotinib and osimertinib were collected and processed si-
milarly in order to measure long-term drug exposure. All samples were
analyzed and used for incurred sample reanalysis (Section 2.7). Fur-
thermore, a blood sample from a 60-year old male patient, who was
treated with osimertinib for more than six months, was collected ap-
proximately four hours after oral intake and transported on ice
(T=0 °C), after which it was centrifuged and preserved similar to the
afatinib study samples. Informed consent was obtained prior to col-
lection. Besides demonstration of clinical applicability, this blood was
used to perform the stability experiments which are described in
Section 2.8.
2.7. Incurred sample reanalysis
To verify the reliability of study sample analyte concentrations,
incurred sample reanalysis was performed, for which patient plasma
samples from Section 2.6 were reanalyzed in two separate runs. A total
of 6 patient samples were analyzed for each compound. The percentage
difference of the results between the first measurement and the repeat
measurement is determined with the following equation: (repeat mea-
surement−first measurement) ∗ 100 /mean.
2.8. Stability of osimertinib
Additional experiments focusing on the stability of osimertinib were
performed to further determine its stability throughout sample hand-
ling and processing. Moreover, it could lead to a potential solution for
the possible instability. Pooled QC's (QC low, high and diluted) and
blood from the patient treated with osimertinib as described in Section
2.6, were stored on ice, at ambient temperature and in a water bath at
T= 37 °C, respectively. After 1, 2, 3, 5 and 24 h, QC samples were re-
frozen at T < −70 °C. At the same pre-set time points, the blood
samples were processed, prior to refreezing them at T < −70 °C.
Firstly, the blood samples had to be centrifuged at 2500×g at ambient
temperature for 5min to obtain the plasmatic supernatant, which was
subsequently transferred to a 1.5-mL Safe-lock vial. Hereafter, all pools
of plasma samples were processed as specified in Section 2.3.
3. Results and discussion
3.1. Method development
The UPLC-MS/MS conditions to achieve optimal sensitivity and
appropriate retention times, were obtained by adding ammonium for-
mate to the water phase. Subsequently, to detect pure peaks, a gradient
at a flow-rate of 0.400mL/min was achieved with mobile phase A,
composed of 10mM ammonium formate (pH 4.5) and mobile phase B,
composed of acetonitrile. Chemical structures, fragmentation patterns
and ion spectra of the analytes are presented in Fig. 1. The product ions
at m/z 112, 396, 260 and 72 were chosen to be MRM ions for quanti-
fication of afatinib, alectinib, crizotinib and osimertinib respectively
and product ions at m/z 371, 265 and 278, for the stable isotope labeled
internal standards afatinib-d6, crizotinib-d5 and erlotinib-d6 respec-
tively. The primary to secondary ion ratio per analyte (except for osi-
mertinib) showed the quality of each generated peak. For afatinib the
ratio of 486.4 > 112.2 to 486.4 > 371.4 was used (ratio 0.9), for
alectinib the ratio of 483.3 > 396.4 to 483.3 > 381.4 (ratio 4.0) and
for crizotinib the ratio 450.3 > 260.4 to 450.3 > 84.2 (ratio 2.0) was
used. For the internal standards afatinib-d6 the ratio 492.0 > 371.2 to
492.0 > 118.3 (ratio 1.2) was used, for erlotinib-d6 the ratio
400.2 > 339.2 to 400.2 > 278.2 (ratio 1.6) and for crizotinib-d5 the
ratio 455.0 > 265.2 to 455.0 > 89.1 was used (ratio 1.7). Osimertinib
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as parent (500.4 m/z in Da) produced only one detectible daughter
compound at 72.1 m/z (Da). Labeled afatinib-d6 (m/z 492 > 371) and
crizotinib-d5 (m/z 455 > 265) proved to be suitable inter standards for
afatinib and crizotinib. Erlotinib-d6 (m/z 400 > 278) occurred to be
the most suitable internal standard for alectinib and osimertinib, where
Heinig et al. used alectinib-d8 [13] and Rood et al. used pazopanib [15]
respectively. This was concluded after multiple testing with various
MKIs. By using a step gradient, all compounds were segregated from
pre-eluting hydrophilic matrix components, which have the potential to
suppress compound responses. In Fig. 2 representative chromatograms
are presented, showing the relatively brief analysis time of 5min with
retention times of 1.2 min for crizotinib, 1.3 min for afatinib, 1.5 min
for the internal standard erlotinib-d6 and 1.6min for alectinib and
osimertinib. A simple deproteinisation step with acetonitrile was suf-
ficient to measure all compounds in plasma in the concentration ranges
as earlier described.
3.2. Assay performance
3.2.1. Specificity and selectivity
Method results for all compounds were linear (r2≥ 0.9965) for the
concentration ranges of 1.00 to 100 ng/mL for afatinib and 10.0 to
1000 ng/mL for alectinib, crizotinib and osimertinib in human plasma.
There was no interference by the blank plasma samples for any MKI or
internal standards. The LLQ's were validated by quantitation of five
replicates of a pool of LLQ's in three separate runs at concentrations of
1.00 ng/mL for afatinib and 10.0 ng/mL for alectinib, crizotinib and
osimertinib. For afatinib, 14 out 15 samples proved to fall within the
defined ACC range of 80–120% with a mean quantitated concentration
of 1.01 ± 0.100 ng/mL. For alectinib, 13 out of 15 samples were ac-
ceptable with 9.04 ± 0.979 ng/mL as average concentration. For cri-
zotinib, 14 out of 15 samples proved to fall within the acceptable range
with an 11.0 ± 1.04 ng/mL mean concentration. All 15 osimertinib
samples were acceptable with 10.6 ± 0.932 ng/mL as average con-
centration. Additionally, blank human plasma from 10 unique subjects
was spiked to obtain concentrations of 1.00 ng/mL for afatinib and
10.0 ng/mL for alectinib, crizotinib and osimertinib and analyzed
during one run. After measurement of the spiked plasma samples, 8 out
of 10 afatinib and alectinib samples proved to fall within the defined
ACC range of 80–120% with mean quantitated concentrations of
0.870 ± 0.108 ng/mL and 8.64 ± 0.783 ng/mL respectively. For cri-
zotinib, this was 9 out 10 and for osimertinib 10 out 10, with average
measured concentrations of 10.1 ± 1.29 ng/mL and 10.1 ± 0.824 ng/
mL respectively.
3.2.2. Accuracy and precision
The BRP, WRP and ACC at five predetermined concentrations
(which included LLQ) in human lithium heparinized plasma are shown
in Table 2 and proved to fall within the validation limits as specified by
the FDA [22].
3.2.3. Recovery and matrix effect
Both RE and ME were calculated after analyzing six unique batches
of lithium heparinized plasma spiked with all MKIs at concentrations of
QC low, middle and high. No major ME (matrix factor close to 1.0) was
observed while the recovery was ≥85% (see Table 3).
Fig. 1. Selected transitions, proposed fragmentations and ion spectra for afatinib (A), alectinib (B), crizotinib (C) and osimertinib (D).
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3.2.4. Short-term, long-term and (autosampler) storage stability
Concerning stability, all compounds were stable in human plasma
following three freeze-thaw cycles and after sample processing for a
minimum of 11 h when samples were kept in the self-cooled auto-
sampler at T= 10 °C (see Table 3). Table 4 shows afatinib, alectinib and
crizotinib to be stable for at least 24 h on ice and at ambient tem-
perature. Section 3.2.5 focusses especially on the stability of osi-
mertinib. Alectinib and crizotinib were stable in a water bath
(T=37 °C) for at least 24 h, while afatinib concentrations decreased
below 80% after 5 h. All compounds were stable in lithium heparinized
plasma for minimally 9months during storage at T < −70 °C (see
Table 3).
3.2.5. Stability of osimertinib
In the paper about osimertinib by Rood et al. a full validation was
conducted [15]. Focusing hereby on stability tests, only results at room
temperature (T= 22 °C) were published, for an unknown length of time
(4 or 6 h) though. Albeit this could be considered surmountable when
other results underline osimertinib's short term stability in plasma,
which the authors claim, other research by Dickinson et al. shows osi-
mertinib to be highly unstable in human plasma after incubation at
37 °C for 6 h [17]. Given the vast discrepancy between the 88.6–92.6%
found by Rood et al. and< 1% by Dickinson et al. [15,17], it is im-
probable to know how osimertinib samples should be handled before
analysis. In order to provide a definite answer to this question, extended
stability tests were conducted, in which sets of plasma samples (QC low,
high and diluted) were stored on ice, at ambient temperature and in a
water bath at T= 37 °C. After being exposed to these experimental
conditions for 1, 2, 3, 5 and 24 h, all samples sets were analyzed. The
results are shown in Table 4. Considering the FDA guidelines [22], all
results had to fall in an 85–115% range to be titled as stable. At ambient
temperature, QC low and high were stable for 3 h and QC diluted for
only 2 h. After that, concentrations decreased further until < 20% after
24 h. Osimertinib is therefore an unstable compound in human plasma
at ambient temperature. For all QC samples at T=37 °C, concentra-
tions decreased so fast that after 1 h none remained>70% and all were
not quantifiable after 24 h (Table 4).
Fig. 2. Representative chromatograms of a double blank processed plasma
sample (A), a plasma sample spiked at the concentration of the LLQ (B), a
plasma sample collected after afatinib administration containing 11.7 ng/mL
afatinib, a plasma sample collected after osimertinib administration containing
167 ng/mL osimertinib (C) and internal standards afatinib-d6 (D), crizotinib-d5
(E) and erlotinib-d6 (F).
Table 2
Calculations of the between-run and within-run precisions and the average
accuracy of the LLQ and QC samples.a
Sample Spiked
(nM)
GM
(nM)
ACC
(%)
WRP
(%)
BRP
(%)
nc
Afatinib
LLQ 1.00 1.01 101.0 9.40 3.62 14
Low 3.00 3.04 101.3 6.58 4.00 14
Middle 40.0 39.6 99.0 2.52 4.25 15
High 80.0 79.1 98.9 2.69 4.53 15
Diluted 800 791 98.9 3.44 3.76 15
Osimertinib
LLQ 10.0 10.6 106.0 6.73 6.69 15
Low 30.0 29.3 97.7 6.94 #b 15
Middle 400 372 93.0 6.71 #b 15
High 800 806 100.8 4.41 7.22 15
Diluted 8000 7135 89.2 5.20 0.814 13
Crizotinib
LLQ 10.0 11.0 110.0 8.56 4.66 14
Low 30.0 31.4 104.7 7.67 2.64 14
Middle 400 426 106.5 7.21 5.46 15
High 800 833 104.1 8.33 4.14 12
Diluted 8000 7881 98.5 7.33 #b 15
Alectinib
LLQ 10.0 9.04 90.4 6.50 10.2 13
Low 30.0 31.1 103.7 2.24 3.06 15
Middle 400 384 96.0 5.55 6.02 14
High 800 797 99.6 9.14 7.17 14
Diluted 8000 7344 91.8 5.57 6.63 14
Abbreviations: GM, grand mean; WRP, within-run precision; BRP, between-run
precision; ACC, average accuracy;
a n= 5 in 3 separate runs.
b No additional variation observed by performing the assay in different runs.
c Number of individual samples falling within acceptable range of accuracy
of 85–115% (80–120% at LLQ).
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Since osimertinib is a covalently binding MKI, it has the potency to
form irreversible Michael adducts with nucleophiles, e.g. plasma al-
bumin, which could be an explanation for its instability in (human)
plasma. This concept is clearly illustrated by Dickinsons et al. [17]:
independent of concentration, only approximately 10% of osimertinib
remained measurable in human serum albumin solution after incuba-
tion at T= 10 °C for 6 h. This chemical reaction can be overcome by
thermic inactivation, reaching T= 0 °C by working on ice: Table 4
shows osimertinib concentrations do not decrease below 90%, thus
being stable in plasma for at least 24 h. Moreover, stock solutions re-
mained stable at ambient temperature for 24 h.
Extrapolating these findings to clinical and laboratory practice,
stability of osimertinib in blood samples had to be tested additionally,
since it will determine how these samples should be handled con-
cerning thermic storage conditions after blood withdrawal. Blood
samples were tested after same exposure conditions (on ice, at ambient
temperature and in a water bath at T= 37 °C) and at same time points
(1, 2, 3, 5 and 24 h) as plasma. The results are presented in Table 5.
Osimertinib was unstable in plasma at ambient temperature, as well as
in blood and at T=37 °C. Comparing osimertinib's stability in plasma
(Table 4) to whole blood (Table 5), osimertinib is almost 5 times more
stable in whole blood at ambient temperature and at T=37 °C. By
centrifuging whole blood, i.e. separating plasma from erythrocytes, the
plasma concentrations of both osimertinib and nucleophiles (e.g. al-
bumin) rise. We hypothesize that this could accelerate the formation of
the earlier mentioned Michael adducts and could therefore cause the
Table 3
Extraction recovery, matrix effect and stability data.
Level Extraction recovery Matrix effect Stability
3 F/T Autosampler (11 h) Long-term (9months)
(ng/mL) (%) (%) (%) (%) (%)
Afatinib
3.00 95.3 ± 8.82 125 ± 1.84 116 ± 7.36 99.4 ± 8.72 93.8 ± 3.56
40.0 116 ± 2.66 125 ± 2.91 ND ND ND
80.0 100 ± 3.53 121 ± 4.73 99.8 ± 6.19 102 ± 3.05 101 ± 0.773
800.0 ND ND 97.9 ± 3.03 107 ± 6.80 ND
Alectinib
30 101 ± 2.45 101 ± 2.03 107 ± 0.908 96.7 ± 0.885 95.6 ± 0.669
400 87.2 ± 1.75 96.3 ± 3.29 ND ND ND
800 84.9 ± 0.99 97.9 ± 5.27 101 ± 1.88 103 ± 17.7 103 ± 0.677
8000 ND ND 100 ± 1.36 97.7 ± 4.55 ND
Osimertinib
30 89.7 ± 8.41 133 ± 3.15 86.4 ± 12.5 91.5 ± 9.05 108 ± 1.35
400 85.2 ± 1.91 107 ± 3.29 ND ND ND
800 85.5 ± 1.28 107 ± 4.60 102 ± 2.29 98.5 ± 3.68 92.9 ± 1.27
8000 ND ND 97.5 ± 1.30 95.2 ± 2.77 ND
Crizotinib
30 112 ± 8.11 105 ± 2.98 99.9 ± 5.62 96.2 ± 1.70 105 ± 1.75
400 104 ± 2.41 112 ± 3.06 ND ND ND
800 106 ± 4.71 110 ± 4.48 104 ± 7.67 101 ± 2.14 109 ± 2.32
8000 ND ND 92.2 ± 1.67 98.6 ± 2.56 ND
Abbreviations: ND, not done; F/T, freeze-thaw cycles.
Table 4
Stability in plasma samples at different storage conditions.
Time (hrs) Afatinib (%) Alectinib (%) Crizotinib (%) Osimertinib (%)
Ice Ambient 37° Ice Ambient 37° Ice Ambient 37° Ice Ambient 37°
QC-LOW
0 100 100 100 100 100 100 100 100 100 100 100 100
1 92.8 115 91.4 103 104 104 99.3 102 95.6 95.6 95.7 54.2
2 99.1 118 90.3 100 102 102 105 94.8 105 92.7 81.3 NQ
3 96.8 108 82.8 98.6 103 99.3 111 102 99.2 90.3 81.2 NQ
5 102 120 82.2 101 107 101 101 109 99.2 93.9 71.7 NQ
24 98.0 95.0 48.3 96.1 109 110 99.5 96.9 106 91.0 12.9 NQ
QC-HIGH
0 100 100 100 100 100 100 100 100 100 100 100 100
1 103 101 93.9 100 99.3 107 109 106 98.3 102 96.5 61.9
2 104 100 91.2 101 102 110 104 102 105 104 91.7 33.8
3 104 102 91.4 101 107 111 103 114 100 102 91.1 18.7
5 104 95.2 93.0 101 105 113 97.0 92.0 107 103 87.5 4.55
24 104 93.0 67.0 100 116 122 99.1 92.0 104 100 18.3 NQ
QC-DILUTED
0 100 100 100 100 100 100 100 100 100 100 100 100
1 101 98.0 94.9 100 100 99.3 98.2 92.8 94.7 102 91.3 55.0
2 101 101 93.6 101 100 103 98.6 103 101 102 86.6 28.9
3 98.2 101 92.3 96.0 101 102 90.6 112 96.5 97.9 76.1 12.5
5 98.5 106 89.9 99.3 105 102 89.8 101 97.0 99.9 67.2 4.48
24 102 95.5 70.2 96.7 101 109 83.7 91.8 101 98.5 12.9 NQ
Abbreviation: NQ, not quantifiable.
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faster decline of osimertinib concentration in plasma. Similar to plasma
samples, storing blood samples on ice (at T= 0 °C) kept osimertinib
stable for at least 24 h. Therefore, as strong advice for laboratory and
clinical practice, samples should be processed solely on ice.
3.3. Clinical applicability
This validated analytical method was used in adequately quanti-
fying the first samples from five patients enrolled in a pharmacokinetic
study in which afatinib was orally administered for six weeks after a
run-in phase. A representative chart with the mean plasma concentra-
tion-time profile of four patients treated with 40mg afatinib is pre-
sented in Fig. 3. Moreover, the method was used to quantify con-
centrations of alectinib, crizotinib and osimertinib in patient plasma
samples (shown in Table 6). All analytes fell within the measurable
concentration range. Furthermore, this analytical method was suc-
cessfully applied to the osimertinib patient sample that was used for
stability experiments and from which results are shown in Table 5.
3.4. Incurred sample reanalysis
The results of the incurred sample reanalysis are presented in
Table 6. All of the samples met the acceptance criteria with mean dif-
ferences between the original and repeated analysis of afatinib, alec-
tinib, crizotinib and osimertinib of −4.8%, −2.0%, 1.9% and −3.0%
respectively.
3.5. Assay performance compared to existing methodologies
When comparing the performance results of this newly developed
assay to existing methodologies [13–16], this assay has comparable
results concerning all FDA validation standards [22]. Only Rood et al.
[15] and Heinig et al. [13] reported incurred sample reanalysis.
Moreover, our extraction recovery (85–100%) for alectinib was sig-
nificantly higher compared to Heinig et al. (< 70%) [13]. Furthermore,
this assay focused more specifically on short-term stability with dif-
ferent storage temperatures up to 24 h, where Rood et al. [15] and
Sparidans et al. [16] only tested short-term stability for 4 or 6 and 8 h
respectively. Hence, this is a more efficient assay to quantify the most
important MKI's for the treatment of EGFR- or ALK-mutated NSCLC.
4. Conclusion
A sensitive and selective method was developed and validated for
the simultaneous analysis of afatinib, alectinib, crizotinib and osi-
mertinib in human lithium heparinized plasma. This method met all the
requirements for bioanalytical method validation of the FDA and will
be used in present and future (clinical) pharmacokinetic studies. Given
osimertinib's instability at ambient temperature in plasma and blood, a
strong recommendation for sample handling must be made: to mini-
mize deprivation of osimertinib, both blood and plasma samples should
be kept and processed solely on ice (at T=0 °C). Otherwise, precise
measurement of osimertinib concentrations is impossible to be used in
Therapeutic Drug Monitoring.
Conflict of interest statement
None.
References
[1] B.A. Chan, B.G. Hughes, Targeted therapy for non-small cell lung cancer: current
standards and the promise of the future, Transl. Lung Cancer Res. 4 (2015) 36–54,
https://doi.org/10.3978/j.issn.2218-6751.2014.05.01.
[2] M. Shea, D.B. Costa, D. Rangachari, Management of advanced non-small cell lung
cancers with known mutations or rearrangements: latest evidence and treatment
approaches, Ther. Adv. Respir. Dis. 10 (2016) 113–129, https://doi.org/10.1177/
Table 5
Stability in whole blood at different storage conditions.
Time (hrs) Osimertinib (%)
Ice Ambient 37°
0 100 100 100
1 101 101 98.8
2 104 100 74.7
3 103 100 64.1
5 105 97.6 46.9
24 108 66.5 18.4
Fig. 3. Mean plasma concentration-time profile of afatinib after an oral dose of
40mg (n= 4).
Table 6
Incurred sample reanalysis.
Compound First analysis Second analysis Mean % Difference
Conc. (ng/mL) Conc. (ng/mL) Conc. (ng/mL) (%)
Afatinib
1 11.4 10.9 11.2 −4.5
2 19.3 16.8 18.1 −13.9
3 17.4 16.3 16.9 −6.5
4 21.4 19.8 20.6 −7.8
5 16.6 16.6 16.6 0.0
6 14.6 15.2 14.9 4.0
Alectinib
1 1125 1075 1100 −4.5
2 1065 1016 1041 −4.7
3 1071 1024 1048 −4.5
4 836 832 834 −0.5
Crizotinib
1 316 295 306 −6.9
2 550 627 589 13.1
3 386 392 389 1.5
4 490 468 479 −4.6
5 588 623 606 5.8
6 396 406 401 2.5
Osimertinib
1 238 231 235 −3.0
2 153 157 155 2.6
3 130 124 127 −4.7
4 174 171 173 −1.7
5 182 167 175 −8.6
6 266 259 263 −2.7
% Difference: (first analysis− second analysis) / (mean of first and second
analysis) ∗ 100.
G.D.M. Veerman, et al. Journal of Chromatography B 1113 (2019) 37–44
43
1753465815617871.
[3] A.S. Tsao, G.V. Scagliotti, P.A. Bunn Jr., D.P. Carbone, G.W. Warren, C. Bai, H.J. de
Koning, A.U. Yousaf-Khan, A. McWilliams, M.S. Tsao, P.S. Adusumilli, R. Rami-
Porta, H. Asamura, P.E. Van Schil, G.E. Darling, S.S. Ramalingam, D.R. Gomez,
K.E. Rosenzweig, S. Zimmermann, S. Peters, S.H. Ignatius Ou, T. Reungwetwattana,
P.A. Janne, T.S. Mok, H.A. Wakelee, R. Pirker, J. Mazieres, J.R. Brahmer, Y. Zhou,
R.S. Herbst, V.A. Papadimitrakopoulou, M.W. Redman, M.W. Wynes, D.R. Gandara,
R.J. Kelly, F.R. Hirsch, H.I. Pass, Scientific advances in lung cancer 2015, J. Thorac.
Oncol. 11 (2016) 613–638, https://doi.org/10.1016/j.jtho.2016.03.012.
[4] F.D.A. U.S., Approval Rapport GILOTRIF™ (Afatinib) Reference ID: 3340037, re-
vised 07 (2013).
[5] M.E. Arcila, G.R. Oxnard, K. Nafa, G.J. Riely, S.B. Solomon, M.F. Zakowski,
M.G. Kris, W. Pao, V.A. Miller, M. Ladanyi, Rebiopsy of lung cancer patients with
acquired resistance to EGFR inhibitors and enhanced detection of the T790M mu-
tation using a locked nucleic acid-based assay, Clin. Cancer Res. 17 (2011)
1169–1180, https://doi.org/10.1158/1078-0432.CCR-10-2277.
[6] J.L. Kuiper, D.A. Heideman, E. Thunnissen, M.A. Paul, A.W. van Wijk, P.E. Postmus,
E.F. Smit, Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated
NSCLC-patients, Lung Cancer 85 (2014) 19–24, https://doi.org/10.1016/j.lungcan.
2014.03.016.
[7] L.V. Sequist, B.A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B. Turke, P. Fidias,
K. Bergethon, A.T. Shaw, S. Gettinger, A.K. Cosper, S. Akhavanfard, R.S. Heist,
J. Temel, J.G. Christensen, J.C. Wain, T.J. Lynch, K. Vernovsky, E.J. Mark,
M. Lanuti, A.J. Iafrate, M. Mino-Kenudson, J.A. Engelman, Genotypic and histolo-
gical evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci. Transl.
Med. 3 (2011) 75ra26, https://doi.org/10.1126/scitranslmed.3002003.
[8] H.A. Yu, M.E. Arcila, N. Rekhtman, C.S. Sima, M.F. Zakowski, W. Pao, M.G. Kris,
V.A. Miller, M. Ladanyi, G.J. Riely, Analysis of tumor specimens at the time of
acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung
cancers, Clin. Cancer Res. 19 (2013) 2240–2247, https://doi.org/10.1158/1078-
0432.CCR-12-2246.
[9] F.D.A. U.S., Approval Rapport TAGRISSO™ (Osimertinib) Reference ID: 3846512,
Revised: 11 (2015).
[10] J.C. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong,
K.H. Lee, A. Dechaphunkul, F. Imamura, N. Nogami, T. Kurata, I. Okamoto, C. Zhou,
B.C. Cho, Y. Cheng, E.K. Cho, P.J. Voon, D. Planchard, W.C. Su, J.E. Gray, S.M. Lee,
R. Hodge, M. Marotti, Y. Rukazenkov, S.S. Ramalingam, F. Investigators,
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N.
Engl. J. Med. 378 (2018) 113–125, https://doi.org/10.1056/NEJMoa1713137.
[11] F.D.A. U.S., Approval Rapport XALKORI® (Crizotinib) Reference ID: 3089187,
Revised: 02 (2012).
[12] F.D.A. U.S., Approval Rapport ALECENSA® (Alectinib) Reference ID: 3859407,
Revised: 12 (2015).
[13] K. Heinig, K. Miya, T. Kamei, E. Guerini, D. Fraier, L. Yu, S. Bansal, P.N. Morcos,
Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and
impact on PK assessment, Bioanalysis 8 (2016) 1465–1479, https://doi.org/10.
4155/bio-2016-0068.
[14] M.S. Roberts, D.C. Turner, A. Broniscer, C.F. Stewart, Determination of crizotinib in
human and mouse plasma by liquid chromatography electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS), J. Chromatogr. B Anal. Technol.
Biomed. Life Sci. 960 (2014) 151–157, https://doi.org/10.1016/j.jchromb.2014.
04.035.
[15] J.J.M. Rood, M.T.J. van Bussel, J.H.M. Schellens, J.H. Beijnen, R.W. Sparidans,
Liquid chromatography-tandem mass spectrometric assay for the T790M mutant
EGFR inhibitor osimertinib (AZD9291) in human plasma, J. Chromatogr. B Anal.
Technol. Biomed. Life Sci. 1031 (2016) 80–85, https://doi.org/10.1016/j.jchromb.
2016.07.037.
[16] R.W. Sparidans, H. Rosing, J.J.M. Rood, J.H.M. Schellens, J.H. Beijnen, Liquid
chromatography-tandem mass spectrometric assay for therapeutic drug monitoring
of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and ge-
fitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma,
J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1033-1034 (2016) 390–398,
https://doi.org/10.1016/j.jchromb.2016.09.012.
[17] P.A. Dickinson, M.V. Cantarini, J. Collier, P. Frewer, S. Martin, K. Pickup,
P. Ballard, Metabolic disposition of osimertinib in rats, dogs, and humans: insights
into a drug designed to bind covalently to a cysteine residue of epidermal growth
factor receptor, Drug Metab. Dispos. 44 (2016) 1201–1212, https://doi.org/10.
1124/dmd.115.069203.
[18] R.W. van Leeuwen, T. van Gelder, R.H. Mathijssen, F.G. Jansman, Drug-drug in-
teractions with tyrosine-kinase inhibitors: a clinical perspective, Lancet Oncol. 15
(2014) e315–e326, https://doi.org/10.1016/S1470-2045(13)70579-5.
[19] R.B. Verheijen, H. Yu, J.H.M. Schellens, J.H. Beijnen, N. Steeghs, A.D.R. Huitema,
Practical recommendations for therapeutic drug monitoring of kinase inhibitors in
oncology, Clin. Pharmacol. Ther. 102 (2017) 765–776, https://doi.org/10.1002/
cpt.787.
[20] H. Rosing, W.Y. Man, E. Doyle, A. Bult, J.H. Beijnen, Bioanalytical liquid chroma-
tographic method validation. A review of current practices and procedures, J. Liq.
Chromatogr. R T 23 (2000) 329–354, https://doi.org/10.1081/JLC-100101455.
[21] P. de Bruijn, I.M. Moghaddam-Helmantel, M.J. de Jonge, T. Meyer, M.H. Lam,
J. Verweij, E.A. Wiemer, W.J. Loos, Validated bioanalytical method for the quan-
tification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human
plasma and urine by liquid chromatography/tandem triple-quadrupole mass spec-
trometry, J. Pharm. Biomed. Anal. 50 (2009) 977–982, https://doi.org/10.1016/j.
jpba.2009.06.048.
[22] F.D.A. U.S., Guidance for Industry: Bioanalytical Method Validation, (May 2018).
G.D.M. Veerman, et al. Journal of Chromatography B 1113 (2019) 37–44
44
